PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
41.00%
Gross profit growth under 50% of GNPX's 629.75%. Michael Burry would be concerned about a severe competitive disadvantage.
27.93%
EBIT growth 1.25-1.5x GNPX's 23.11%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
27.93%
Operating income growth 1.25-1.5x GNPX's 23.11%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
29.77%
Net income growth 1.25-1.5x GNPX's 23.48%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
30.61%
EPS growth 1.25-1.5x GNPX's 25.56%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
30.61%
Diluted EPS growth 1.25-1.5x GNPX's 25.56%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
2.13%
Share count expansion well above GNPX's 2.91%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.13%
Diluted share count expanding well above GNPX's 2.92%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
32.67%
Positive OCF growth while GNPX is negative. John Neff would see this as a clear operational advantage vs. the competitor.
32.86%
Positive FCF growth while GNPX is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.05%
10Y OCF/share CAGR above 1.5x GNPX's 36.47%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
75.83%
5Y OCF/share CAGR above 1.5x GNPX's 38.96%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
20.41%
3Y OCF/share CAGR 1.25-1.5x GNPX's 15.00%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
95.17%
Net income/share CAGR above 1.5x GNPX's 35.54% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
79.59%
5Y net income/share CAGR 1.25-1.5x GNPX's 56.19%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
2.82%
Below 50% of GNPX's 24.42%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
170.99%
Positive growth while GNPX is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-42.91%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-60.55%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while GNPX invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-18.27%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-4.43%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-31.86%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-15.50%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.